GSK offloads shigella vaccine to Bharat ahead of phase 3, vows to support fundraising
GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial design and fundraising, framed the deal as a way to get the vaccine to patients in low- and middle-income countries where the pathogen is a health threat.
GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial design and fundraising, framed the deal as a way to get the vaccine to patients in low- and middle-income countries where the pathogen is a health threat.
